Coldstream Capital Management Inc. Purchases Shares of 1,654 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Coldstream Capital Management Inc. acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the fourth quarter, HoldingsChannel reports. The firm acquired 1,654 shares of the biotechnology company’s stock, valued at approximately $201,000.

A number of other institutional investors also recently made changes to their positions in SRPT. World Investment Advisors LLC bought a new position in shares of Sarepta Therapeutics during the third quarter valued at about $2,418,000. Tidal Investments LLC grew its position in Sarepta Therapeutics by 91.2% during the 3rd quarter. Tidal Investments LLC now owns 5,634 shares of the biotechnology company’s stock worth $704,000 after acquiring an additional 2,688 shares during the last quarter. GAMMA Investing LLC grew its position in Sarepta Therapeutics by 27.7% during the 4th quarter. GAMMA Investing LLC now owns 854 shares of the biotechnology company’s stock worth $104,000 after acquiring an additional 185 shares during the last quarter. Everence Capital Management Inc. purchased a new position in Sarepta Therapeutics in the 4th quarter worth approximately $344,000. Finally, Nordea Investment Management AB lifted its position in Sarepta Therapeutics by 19.1% in the fourth quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company’s stock valued at $8,228,000 after purchasing an additional 10,815 shares during the last quarter. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Insider Activity at Sarepta Therapeutics

In other news, Director Claude Nicaise sold 2,491 shares of the company’s stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $99.64, for a total value of $248,203.24. Following the transaction, the director now owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. 7.70% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

Several research analysts recently commented on SRPT shares. Needham & Company LLC decreased their target price on shares of Sarepta Therapeutics from $202.00 to $183.00 and set a “buy” rating on the stock in a research note on Thursday, April 3rd. Wells Fargo & Company started coverage on shares of Sarepta Therapeutics in a research note on Friday, April 11th. They set an “overweight” rating and a $115.00 price objective for the company. Piper Sandler dropped their target price on shares of Sarepta Therapeutics from $182.00 to $110.00 and set an “overweight” rating for the company in a report on Monday, April 21st. Morgan Stanley lowered their price target on Sarepta Therapeutics from $196.00 to $182.00 and set an “overweight” rating for the company in a research report on Friday, April 11th. Finally, Deutsche Bank Aktiengesellschaft dropped their price objective on Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a report on Wednesday, March 19th. Six equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sarepta Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $158.70.

Sarepta Therapeutics Stock Up 1.2 %

Shares of NASDAQ:SRPT opened at $63.51 on Friday. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The stock has a fifty day simple moving average of $72.86 and a two-hundred day simple moving average of $103.71. Sarepta Therapeutics, Inc. has a 12-month low of $48.01 and a 12-month high of $173.25. The stock has a market capitalization of $6.24 billion, a price-to-earnings ratio of 50.81 and a beta of 0.93.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.